Henderson Jane SEC Filing Summary

Jane Henderson, Chief Financial Officer of Apogee Therapeutics, Inc., reported a sale of 1500 shares of common stock on December 19, 2025. The transaction was executed at a price of $80.00 per share, resulting in a total sale value of $120,000. This sale was conducted under a Rule 10b5-1 trading plan adopted on September 27, 2024. Following this transaction, Ms. Henderson owns 193,371 shares of Apogee Therapeutics, Inc. common stock directly.